| Audience | Adults and adolescents affected by cannabis use disorder, families, addiction clinicians, primary-care clinicians, and readers following cannabis treatment research |
| Primary Topic | varenicline for cannabis use disorder |
| Source | Read the full source | Review on CEDClinic.com | Another Review on this at CED Clinic |
Varenicline for Cannabis Use Disorder: What Five Studies Show
A new systematic review found mixed and insufficient evidence for varenicline as a treatment for cannabis use disorder. Five studies involving 299 participants were too heterogeneous for meta-analysis, and only one was rated high quality.
| Study Type | Preregistered systematic review with narrative synthesis |
| Population | Adolescents and adults with cannabis use or cannabis use disorder |
| Evidence Base | Five studies, 299 total participants |
| Included Designs | Four randomized controlled trials and one case series |
| Search Coverage | Nine bibliographic and trial-registry sources, with final extraction in March 2025 |
| Primary Question | Whether varenicline reduces cannabis use or cannabis use disorder outcomes |
| Secondary Questions | Tolerability and effects on concurrent tobacco use |
| Main Result | Mixed findings across studies; the single high-quality study reported reductions in cannabis use and withdrawal symptoms |
| Tolerability | Inconsistent across three studies; nausea was more frequent with varenicline in the high-quality study, without a difference in experiencing at least one adverse event |
| Tobacco Outcome | Inconsistent across four studies; the high-quality study found no difference in cigarettes per day |
| Journal | Journal of Substance Use and Addiction Treatment |
| Published | August 15, 2026 |
| PMID / DOI | 42603629 / 10.1016/j.josat.2026.210090 |
| Major Limitation | Only five heterogeneous studies, with two rated poor quality and only one rated good |
The review found five eligible studies involving 299 participants: four randomized trials and one case series.
That is a narrow foundation for judging a treatment intended for a common and clinically heterogeneous disorder.
The single high-quality study reported reductions in cannabis use and withdrawal symptoms.
Across all studies, however, efficacy findings were inconsistent, and the methods were too different for a meaningful meta-analysis.
Three studies reported tolerability outcomes, with inconsistent results.
In the high-quality study, the proportion experiencing at least one adverse event did not differ between groups, although nausea was more frequent with varenicline.
Four studies measured concurrent tobacco use and produced inconsistent findings.
The high-quality study found no difference in cigarettes smoked per day during treatment.
Two included studies were rated poor quality, two fair, and only one good.
The review authors concluded that current data are insufficient for confident conclusions about efficacy and tolerability in either youth or adults.
Medication development for cannabis use disorder has repeatedly produced small or inconsistent signals. Behavioral treatments remain the better-established foundation while pharmacotherapy research continues.
A recent randomized varenicline trial found no overall treatment effect on weekly cannabis-use sessions, although a sex interaction favored men. That subgroup result is important to study, but it does not reverse the review’s overall conclusion of insufficient evidence.
The most useful result here is the authors’ restraint. One better-quality study can create a promising signal, but it cannot compensate for a five-study literature with inconsistent methods and mixed findings.
For patients, this is not a reason to seek varenicline as a proven cannabis treatment. It is a reason to support better trials and to keep current care focused on careful assessment, psychosocial treatment, withdrawal support, and concurrent tobacco or mental-health needs.
How to Read a Promising but Inconclusive Treatment Review
A positive finding in one good study can justify more research.
It cannot establish treatment efficacy when the overall literature is small, heterogeneous, and mixed.
Four distinctions that matter
Signal versus conclusion
A favorable result in the best study is a signal, while the total evidence base determines whether a confident conclusion is possible.
Randomized trials versus a coherent evidence base
Four randomized trials sound substantial, but incompatible methods and outcomes prevented quantitative pooling.
Any adverse event versus specific adverse events
No group difference in having at least one adverse event does not mean the profiles were identical; nausea was more frequent with varenicline in the high-quality study.
Off-label possibility versus established care
Biological plausibility and early data do not make varenicline an approved or proven cannabis use disorder treatment.
The Same Study Can Mean Different Things Depending on the Question Being Asked
Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses.
Promising Does Not Mean Proven
The review found mixed evidence and could not establish that varenicline reliably reduces cannabis use.
Do not start, stop, or repurpose varenicline without a clinician who can address cannabis, tobacco, withdrawal, and mental health together.
Keep Established Care Central
The literature is too small and inconsistent to support routine varenicline treatment for cannabis use disorder.
Assessment, motivational and behavioral care, contingency approaches where available, withdrawal management, and co-occurring conditions remain central.
Five Studies Cannot Carry Broad Claims
Two studies were poor quality and only one was good.
Narrative synthesis was necessary because outcomes and methods were not compatible enough for pooling.
Outcome Inconsistency Limits Confidence
Cannabis use, withdrawal, tolerability, and tobacco outcomes were not measured consistently across studies.
That heterogeneity makes it difficult to estimate who might benefit, by how much, and at what cost in adverse effects.
The New Trial Still Had a Null Overall Result
A recent 174-person randomized trial reported no overall treatment effect on weekly cannabis-use sessions.
A sex interaction favored men, but subgroup findings require replication and should not be generalized.
Cannabis and Tobacco Need Separate Measurement
Varenicline is established for smoking cessation, which can complicate interpretation when patients use both cannabis and tobacco.
Trials should measure both substances clearly and distinguish direct cannabis effects from tobacco-related change.
Larger Harmonized Trials Are Needed
Future studies should prespecify cannabis-use, abstinence, withdrawal, retention, and adverse-event outcomes.
Adequate representation and powered analyses by sex and age are necessary before subgroup claims become actionable.
No Approved Medication for CUD
The absence of an approved medication creates pressure to overread early pharmacotherapy signals.
Public communication should state clearly that evidence remains insufficient and that off-label use is not established efficacy.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan
Want to discuss this topic with other patients and caregivers? Join the forum discussion
When a new paper overlaps with earlier CED Clinic coverage, we preserve the chain instead of hiding the overlap. These links point to older related posts so readers can compare what is new, what is repeated, and how the evidence has moved.
GLP-1 receptor agonists show promise in reducing alcohol consumption and cravings, as well as supporting nicotine abstinence. However, more research is needed for stimulant use disorders.
Frequently Asked Questions
What did the systematic review examine?
It examined peer-reviewed studies of varenicline for cannabis use or cannabis use disorder in adolescents and adults, including efficacy, tolerability, and concurrent tobacco use.
How many studies were included?
Five studies with 299 total participants were included: four randomized controlled trials and one case series.
Did varenicline reduce cannabis use?
Results were mixed. The single high-quality study reported reductions in cannabis use and withdrawal symptoms, but the overall evidence was insufficient for a confident conclusion.
Why was there no meta-analysis?
The studies used methods and outcomes that were too heterogeneous for compatible quantitative pooling, so the authors used narrative synthesis.
How strong were the included studies?
Two were rated poor quality, two fair quality, and one good quality.
What did the review find about adverse events?
Tolerability findings were inconsistent. In the high-quality study, the overall proportion with at least one adverse event did not differ, but nausea was more frequent with varenicline.
Did varenicline reduce cigarette smoking?
Findings across four studies were inconsistent, and the high-quality study found no difference in cigarettes per day during treatment.
Is varenicline approved for cannabis use disorder?
No. Varenicline is not an approved treatment for cannabis use disorder, and this review did not establish efficacy for that use.
Does the review apply equally to youth and adults?
No confident age-specific conclusion is possible because the total evidence base was small and heterogeneous.
What is the practical takeaway?
Varenicline remains a research candidate, while current treatment should continue to emphasize established psychosocial care and individualized clinical support.
